Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test may spare gastric cancer patients from unnecessary chemo

NCT ID NCT06609759

First seen May 12, 2026 · Last updated May 25, 2026 · Updated 7 times

Summary

This study looks at whether using a blood test (ctDNA) to guide treatment after surgery for stage II-III gastric cancer works as well as standard chemotherapy. About 197 patients are being observed to see if those with low-risk blood markers can safely receive less intense treatment. The goal is to maintain cancer control while reducing side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE II-III GASTRIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Jinan Central Hospital,

    Jinan, Shandong, China

  • Qilu Hospital of Shandong Univertisy

    Jinan, Shandong, 250012, China

  • Shandong Provincial Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, 250012, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, 266000, China

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, 264000, China

Conditions

Explore the condition pages connected to this study.